CD8A and leukemia: To investigate the in vivo efficacy of the MCJ-deficient CD8 CAR-T cells for the treatment of leukemia, E2a leukemia cells were intravenously (i.v.)injected to the WT host mice, and 3 days later mice received sub-lethal irradiation for lymphodepletion, as previously described79,82,83.